Nkarta Inc.

NKTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.90

+$0.02 (+0.69%)

Sep 22, 2026, 1:58 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.69%

(1D)

Rating

Updated: Aug 10, 2026

24.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $207.12M

1D Range

2.87 2.99

52W Range

1.70 3.72

Valuation (TTM)

PE -1.83

PB 0.83

EV/EBITDA -0.90

Valuation (NTM)

Forward PE N/A

Forward PEG 0.25

Price Target $9

Cash Flow

FCF Yield -45.6%

SBC Adj. FCF Yield -49.2%

SBC Impact -7.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 13.0% | 16.8%

FCF 3Y | 5Y 7.7% | -1.0%

Returns

ROA -34.8%

ROE -39.6%

ROIC -41.1%

Financial Health

Net Cash

$109.23M

Current Ratio 7.98

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a...

Sector Healthcare

Industry Biotechnology

Employees 106

IPO Date Jul 9, 2020

Website www.nkartatx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+210.34%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞